Latest news with #TempusAi
Yahoo
4 days ago
- Business
- Yahoo
Why Tempus AI Stock Plummeted This Week
Tempus AI is a healthcare-oriented artificial intelligence company. Spruce Point Capital Management released a report critical of Tempus AI this week. Investors should exercise caution with Tempus AI stock but not be deterred from considering an investment solely based on the critical report. 10 stocks we like better than Tempus Ai › Extending the more-than-4% slide that they experienced last week, shares of Tempus AI (NASDAQ: TEM) have suffered an even more precipitous decline this week. According to data provided by S&P Global Market Intelligence, the healthcare-oriented artificial intelligence (AI) stock had fallen 13.2% from the end of last Friday's trading session through the market's close on Thursday. The stock's decline can be singularly attributed to a critical report of the company that a short-seller provided on Wednesday. Arguing that investors should be circumspect about the company's financials and its public claims, Spruce Point Capital Management provided the market with a report that questions the credibility of Tempus AI. In addition to questioning the integrity of the company's founder, Eric Lefkofsky, Spruce Point raised doubts about Tempus AI's financial reporting and the nature of its partnership with AstraZeneca -- among other issues. Based on its analysis, Spruce Point stated that Tempus AI stock has the potential to fall about 50% to 60%. From the stock's closing price on Tuesday (the day before Spruce Point released its report), this implies a stock price of $26.35 to $32.94. Founded in 2009, Spruce Point is an investment management firm that focuses on short-selling opportunities. Since Spruce Point stands to profit from Tempus AI stock falling, investors should take its claims with a heaping tablespoon of salt. While it raises some strong accusations against the company, Tempus' supporters are unmoved. Ark Invest, led by Tempus AI bull Cathie Wood, for example, bought 251,080 shares of Tempus AI on Wednesday. At this point, potential investors will want to exercise caution and see how the company responds. Before you buy stock in Tempus Ai, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Tempus Ai wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,985!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $853,108!* Now, it's worth noting Stock Advisor's total average return is 978% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Scott Levine has no position in any of the stocks mentioned. The Motley Fool recommends AstraZeneca Plc. The Motley Fool has a disclosure policy. Why Tempus AI Stock Plummeted This Week was originally published by The Motley Fool
Yahoo
6 days ago
- Business
- Yahoo
Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time.
Tempus AI is a leader in applying AI solutions to cancer diagnosis. The company announced a new platform for speeding up the discovery of new drug targets. Since it's still unprofitable, Tempus AI is an investment with a higher degree of risk. When it comes to shares of Tempus AI (NASDAQ: TEM), many may feel like they're standing on a dock watching the stock sail off to the horizon. It's understandable if you identify with this. After all, shares of Tempus AI, a healthcare-oriented artificial intelligence (AI) leader, have soared more than 54% year to date (as of this writing), while the S&P 500 has plunged over 5%. But there's no need to fret that you've missed the boat on Tempus AI stock. While its climb so far in 2025 is impressive, it's easy to see how this specialist in applying AI to the field of oncology can skyrocket even higher in the future. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Since its founding in 2015, Tempus AI has made great strides in advancing its AI solutions for the treatment of cancer. The company, in fact, characterizes itself as possessing what it "consider[s] to be one of the largest libraries of clinical and molecular oncology data in the world." It's with this resource that Tempus is able to provide physicians with a powerful diagnostic tool that helps to inform better treatment options. And the company continues to develop innovative solutions. Recently, Tempus announced a new tool to help identify new targets for cancer treatment: Tempus Loop. Using patient data, models, and CRISPR screening, Tempus Loop expedites the process of discovering and confirming potential drug targets -- something of incredible value considering what Chief Scientific Officer Kate Sasser recognizes as a "90% failure rate for preclinical assets to become real-world medicines."Essentially, Tempus Loop can be of great assistance to pharmaceutical companies as a way of reducing research and development spending. Already, Tempus has received attention from leading drugmakers. It recently announced an expanded partnership with AstraZeneca (NASDAQ: AZN) to discover new drug targets, among other things. While Tempus is at the forefront of the intersection between AI and oncology, this investment requires higher risk-tolerance at the moment since the business is still unprofitable. Before you buy stock in Tempus Ai, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Tempus Ai wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $611,271!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $684,068!* Now, it's worth noting Stock Advisor's total average return is 889% — a market-crushing outperformance compared to 162% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of April 28, 2025 Scott Levine has no position in any of the stocks mentioned. The Motley Fool recommends AstraZeneca Plc. The Motley Fool has a disclosure policy. Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time. was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
30-04-2025
- Business
- Globe and Mail
Is This the Best Nancy Pelosi Stock to Buy After a 40% Pullback?
In this video, I will talk about Tempus AI (NASDAQ: TEM) and whether it is worth buying after the recent pullback. Watch the short video to learn more, consider subscribing, and click the special offer link below. *Stock prices us ed were from the trading day of April 29, 2025. The video was published on April 29, 2025. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Should you invest $1,000 in Tempus Ai right now? Before you buy stock in Tempus Ai, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Tempus Ai wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $598,818!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $666,416!* Now, it's worth noting Stock Advisor 's total average return is872% — a market-crushing outperformance compared to160%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of April 28, 2025 Neil Rozenbaum has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Neil is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.
Yahoo
25-04-2025
- Business
- Yahoo
Tempus AI Is Skyrocketing Today -- Is the Stock a Buy Right Now?
Amid a bullish backdrop for the broader market, Tempus AI (NASDAQ: TEM) stock is posting big gains Wednesday. The company's share price was up 15.8% as of 1:45 p.m. ET. At the same point in time, the S&P 500 was up 2.1%, and the Nasdaq Composite had risen 2.8%. Investors are having a strong positive reaction to news that the Trump administration is apparently interested in getting a trade deal done with China and lowering tariffs in the not-too-distant future. In addition to buying momentum that's lifting valuations across the broader market, Tempus AI stock is climbing thanks to news that the company has formed a new partnership with AstraZeneca and Pathos AI. The team-up will see the trio of companies working to build an artificial intelligence (AI) model for oncology that can help generate clinical insights, aid in the discovery of new drug targets, and help develop treatments. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Against the backdrop of an 8% decline for the S&P 500, Tempus AI has managed to rocket 48% higher across 2025's trading. As an early, specialized leader in healthcare AI software, the company has plenty of long-term promise -- but its valuation profile also comes with significant risk. The company's revenue increased 30.4% annually last year to reach $693.4 million, and its 55% gross margin in the period looks promising for a business that could still be in very early scaling stages. On the other hand, the company seemingly has a long way to go before shifting into profitability and recorded a net loss of $705.8 million last year. With a market cap of roughly $8.7 billion, Tempus AI is valued at approximately 12.6 times last year's sales. The business has huge expansion potential and will likely continue to serve up very strong revenue growth this year, but its heavily forward-looking valuation suggests the stock is probably only a good fit for investors with high risk tolerance. If you're interested in building a position in this AI healthcare software pure play, I would recommend dollar-cost averaging into the stock due to the potential for macroeconomic and geopolitical developments to spur continued volatility for the market in the near term. Before you buy stock in Tempus Ai, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Tempus Ai wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $561,046!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $606,106!* Now, it's worth noting Stock Advisor's total average return is 811% — a market-crushing outperformance compared to 153% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of April 21, 2025 Keith Noonan has no position in any of the stocks mentioned. The Motley Fool recommends AstraZeneca Plc. The Motley Fool has a disclosure policy. Tempus AI Is Skyrocketing Today -- Is the Stock a Buy Right Now? was originally published by The Motley Fool
